EMA Authorised: CellCept (mycophenolate mofetil) — Roche Registration GmbH

View source ↗

Summary

The European Medicines Agency authorized CellCept (mycophenolate mofetil) by Roche Registration GmbH for preventing graft rejection in transplant patients. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection
• Organ Transplant Rejection

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Graft Rejection. MAH: Roche Registration GmbH. Decision date: 26/03/2026